FOLD Amicus Therapeutics Inc
Price (delayed)
$11.06
Market cap
$3.28B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.39
Enterprise value
$3.52B
Amicus Therapeutics is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics
Highlights
The EPS has grown by 39% YoY and by 20% from the previous quarter
The net income rose by 35% YoY and by 19% QoQ
Amicus Therapeutics's quick ratio has decreased by 8% from the previous quarter
Key stats
What are the main financial stats of FOLD
Market
Valuations
Earnings
Shares outstanding
296.59M
Market cap
$3.28B
Enterprise value
$3.52B
Price to earnings (P/E)
N/A
Price to book (P/B)
24.72
Price to sales (P/S)
7.37
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.71
Revenue
$455.66M
EBIT
-$49.08M
EBITDA
-$40.33M
Free cash flow
-$48.1M
Per share
Balance sheet
Liquidity
EPS
-$0.39
Free cash flow per share
-$0.16
Book value per share
$0.45
Revenue per share
$1.5
TBVPS
$1.75
Total assets
$749.48M
Total liabilities
$616.96M
Debt
$444.06M
Equity
$132.52M
Working capital
$293.64M
Debt to equity
3.35
Current ratio
2.75
Quick ratio
2.05
Net debt/EBITDA
-5.82
Margins
Efficiency
Dividend
EBITDA margin
-8.9%
Gross margin
89.9%
Net margin
-26.2%
Operating margin
-8.8%
Return on assets
-15.9%
Return on equity
-85.9%
Return on invested capital
-8.3%
Return on capital employed
-8.4%
Return on sales
-10.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
FOLD stock price
How has the Amicus Therapeutics stock price performed over time
Intraday
-2.12%
1 week
-3.91%
1 month
-3.57%
1 year
-15.51%
YTD
-22.06%
QTD
11.49%
Financial performance
How have Amicus Therapeutics's revenue and profit performed over time
Revenue
$455.66M
Gross profit
$409.56M
Operating income
-$40.16M
Net income
-$119.54M
Gross margin
89.9%
Net margin
-26.2%
The operating margin has soared by 79% YoY and by 54% QoQ
Amicus Therapeutics's operating income has surged by 73% YoY and by 50% QoQ
FOLD's net margin has surged by 50% year-on-year and by 24% since the previous quarter
The net income rose by 35% YoY and by 19% QoQ
Growth
What is Amicus Therapeutics's growth rate over time
Valuation
What is Amicus Therapeutics stock price valuation
P/E
N/A
P/B
24.72
P/S
7.37
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.71
The EPS has grown by 39% YoY and by 20% from the previous quarter
The P/B is 49% above the 5-year quarterly average of 17.0
The equity has grown by 19% YoY
FOLD's price to sales (P/S) is 33% lower than its 5-year quarterly average of 11.2 and 14% lower than its last 4 quarters average of 8.8
FOLD's revenue is up by 30% year-on-year and by 8% since the previous quarter
Efficiency
How efficient is Amicus Therapeutics business performance
The ROS has soared by 74% YoY and by 49% from the previous quarter
The ROIC has soared by 65% YoY and by 46% from the previous quarter
Amicus Therapeutics's return on equity has increased by 46% YoY and by 22% QoQ
FOLD's ROA is up by 37% YoY and by 19% from the previous quarter
Dividends
What is FOLD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for FOLD.
Financial health
How did Amicus Therapeutics financials performed over time
FOLD's total assets is 21% greater than its total liabilities
FOLD's current ratio is down by 9% since the previous quarter
Amicus Therapeutics's quick ratio has decreased by 8% from the previous quarter
The equity has grown by 19% YoY
FOLD's debt to equity is down by 17% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.